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AbstrACt
Introduction Multimorbidity and polypharmacy are major 
risk factors for potentially inappropriate prescribing (eg, 
overprescribing and underprescribing), and systematic 
medication reviews are complex and time consuming. In 
this trial, the investigators aim to determine if a systematic 
software-based medication review improves medication 
appropriateness more than standard care in older, 
multimorbid patients with polypharmacy.
Methods and analysis Optimising PharmacoTherapy 
In the multimorbid elderly in primary CAre is a cluster 
randomised controlled trial that will include outpatients 
from the Swiss primary care setting, aged ≥65 years with 
≥three chronic medical conditions and concurrent use of 
≥five chronic medications. Patients treated by the same 
general practitioner (GP) constitute a cluster, and clusters 
are randomised 1:1 to either a standard care sham 
intervention, in which the GP discusses with the patient if 
the medication list is complete, or a systematic medication 
review intervention based on the use of the 'Systematic 
Tool to Reduce Inappropriate Prescribing'-Assistant 
(STRIPA). STRIPA is a web-based clinical decision support 
system that helps customise medication reviews. It is 
based on the validated ‘Screening Tool of Older Person’s 
Prescriptions’ (STOPP) and ‘Screening Tool to Alert doctors 
to Right Treatment’ (START) criteria to detect potentially 
inappropriate prescribing. The trial’s follow-up period 
is 12 months. Outcomes will be assessed at baseline, 
6 and 12 months. The primary endpoint is medication 
appropriateness, as measured jointly by the change in the 
Medication Appropriateness Index (MAI) and Assessment 
of Underutilisation (AOU). Secondary endpoints include 
the degree of polypharmacy, overprescribing and 
underprescribing, the number of falls and fractures, 
quality of life, the amount of formal and informal care 
received by patients, survival, patients’ quality adjusted life 
years, patients’ medical costs, cost-effectiveness of the 
intervention, percentage of recommendations accepted by 
GPs, percentage of recommendation rejected by GPs and 
patients’ willingness to have medications deprescribed.
Ethics and dissemination The ethics committee of the 
canton of Bern in Switzerland approved the trial protocol. 
The results of this trial will be published in a peer-
reviewed journal.
Main funding Swiss National Science Foundation, 
National Research Programme (NRP 74) ‘Smarter 
Healthcare’.
strengths and limitations of this study
 ► The Optimising PharmacoTherapy In the multimor-
bid elderly in primary CAre (OPTICA) trial is the first 
randomised controlled trial to examine the effect 
of the 'Systematic Tool to Reduce Inappropriate 
Prescribing'-Assistant, a software-assisted clinical 
decision support tool, on medication appropriate-
ness in older, multimorbid patients with polyphar-
macy in a primary care setting.
 ► OPTICA is the first randomised controlled trial to test 
the use of software-based structured medication re-
views in Swiss primary care.
 ► The OPTICA trial demonstrates how linked and 
coded data from electronic medical records can 
be used to evaluate primary care interventions in a 
randomised controlled trial setting. The investigators 
limit selection bias by using screening lists with a 
random sample of potentially eligible patients and 
randomising general practitioners (GPs) after patient 
recruitment is complete, but cannot eliminate the 
risk of selection bias.
 ► The investigators chose a sham intervention in ac-
cordance with usual care in the control group to im-
prove patient blinding but, by design, they could not 
blind GPs.
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trial registration numbers  Clinicaltrials. gov (NCT03724539), KOFAM 
(Swiss national portal) (SNCTP000003060), Universal Trial Number 
(U1111-1226-8013).
IntroduCtIon
Globally, there is a high prevalence of multimorbidity 
and polypharmacy in people more than 65 years old.1 2 
Multimorbidity is commonly defined as the coexistence 
of three or more chronic diseases,3 and polypharmacy is 
commonly defined as the regular intake of five or more 
medications.4 Polypharmacy is often caused by multi-
morbidity and is linked to a high risk of potentially inap-
propriate prescribing,5 6 which has three main elements, 
namely: (1) overuse, (2) underuse and (3) inappropriate 
use of medications (ie, wrong dose/medication for the 
indication).7
Appropriate polypharmacy denotes a situation in which 
‘medication use is optimised according to the patients’ 
clinical needs’ and in which patients ‘receive the most 
appropriate combinations of medications based on the 
best available evidence’.8 While appropriate polypharmacy 
can improve quality of life and prevent consequences of 
disease, inappropriate polypharmacy can harm patients’ 
health.4 For instance, it can increase the risk of falls and 
fractures,9 lead to cognitive decline,10 11 and it can reduce 
quality of life.9 Polypharmacy also increases the risk of 
drug–drug interactions, drug–disease interactions and 
adverse drug events.12–15 Treatment of older patients with 
multimorbidity and polypharmacy is a complex problem 
in primary care and other medical fields and both condi-
tions are increasingly common as populations age. Due 
to the relatively small number of randomised controlled 
trials on different interventions for the management of 
multimorbid people, there currently remain uncertain-
ties about the effectiveness of these interventions.16 Medi-
cation reviews in older adults with multimorbidity and 
polypharmacy can be complicated and time-consuming.17 
General practitioners (GPs) have reported that time 
limitations and lack of user-friendly and reliable tools 
pose significant barriers to regular medication optimisa-
tion activities in practice.18
Current evidence is ambiguous on whether review inter-
ventions that aim at optimising medication can reduce 
inappropriate polypharmacy. A systematic review and 
meta-analysis of short-term medication review interven-
tions published in 2017 showed that such isolated medi-
cation reviews have an impact on drug-related outcomes, 
but only minimally influence clinical outcomes and have 
no impact on quality of life.19 A more recent systematic 
review and meta-analysis on interventions to improve 
the appropriateness of medication use in older people 
showed that such interventions may be beneficial for 
reducing potential prescribing omissions, but that it 
remains uncertain whether they improve the appropri-
ateness of medication use.20
The increasing use of electronic medical records (EMR) 
and electronic prescribing has opened opportunities to 
incorporate web-based clinical decision support systems 
(CDSS) at the point of care. For instance, a complex 
intervention with an informatics tool and financial incen-
tives has led to a reduction in high-risk prescribing of 
non-steroidal anti-inflammatory drugs and antiplatelet 
medications.21 Medication optimisation studies that use 
CDSS enabled by electronic medical records have shown 
that the interventions are feasible and acceptable to clini-
cians, but evidence that they lead to more appropriate use 
of medications in general and improve clinical outcomes 
is still limited.22
objectives
The primary aim of the cluster-randomised ‘Optimising 
PharmacoTherapy In the multimorbid elderly in primary 
CAre’ (OPTICA) trial is to test whether the use of a 
systematic, software-assisted medication review interven-
tion leads to a more appropriate use of medications than 
a usual care sham intervention. This primary outcome 
will be measured by the Medication Appropriateness 
Index (MAI) and the Assessment of Underutilisation 
(AOU). Secondary outcomes are the degree of polyphar-
macy, the degree of overprescribing, the degree of under-
prescribing, the number of falls and fractures, quality of 
life, the amount of formal and informal care received 
by patients, survival, patients’ quality adjusted life years 
(QALYs), patients’ medical costs, cost-effectiveness of the 
intervention, percentage of recommendations accepted 
and rejected by GPs, and patients’ willingness to have 
medications deprescribed.
MEthods And AnAlysIs
General study design and setting
The OPTICA trial is a cluster randomised controlled trial 
(RCT), coordinated at the Institute of Primary Health-
care of the University of Bern (BIHAM). Participating 
GPs, who will each systematically recruit multimorbid, 
older patients with polypharmacy, define the clusters. 
Through randomisation, the GPs will be allocated to the 
structured medication review or a usual care based sham 
intervention.
The investigators used the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 
checklist when they wrote this protocol.23 Please refer to 
figure 1 for the study flow chart and figure 2 for a descrip-
tion of the data flow within the OPTICA trial.
Cluster definition
The trial will be conducted in about 40 primary care 
offices in the German-speaking regions of Switzerland. 
Each participating GP, who prescribes the medication of 
his/her patients, constitutes a cluster. GPs were recruited 
as subinvestigators from October 2017 until June 2018 
from the pool of teaching physicians at the University of 
Bern and from the group of GPs who attended project 
presentations hosted by the BIHAM throughout 2017 and 
2018. Additional GPs will be recruited throughout 2019 
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Figure 1 OPTICA trial flow chart. Flow diagram of the progress through the phases of the OPTICA trial. In dark grey: steps 
done by general practitioners. In white: steps done by study team at BIHAM. *Target number. BIHAM, Institute of Primary 
Healthcare of the University of Bern; GPs, general practitioners; OPTICA, Optimising PharmacoTherapy In the multimorbid 
elderly in primary CAre; STRIPA, Systematic Tool to Reduce Inappropriate Prescribing-Assistant.
to replace GPs who had to withdraw from the study, as the 
data export to the FIRE database did not work in their GP 
office. Engagement with GPs started early in anticipation 
of slow recruitment, which has been reported in previous 
studies.24 25 All eligible GPs who showed interest in the 
OPTICA trial were visited by the investigators at their GP 
office and given a detailed explanation of the trial.26 As of 
July 2019, 83% of the participating GPs are male. Eighty 
per cent of the GPs work in group practice, while 20% 
work in single practice. Twenty-nine per cent of GPs work 
in the countryside and 71% work in urban and suburban 
areas.
randomisation
Randomisation is done after the cluster has been 
completed. The randomisation is done centrally in a 
web-based system (REDCap) by a study team member 
after all cluster information has been entered. Each 
participating GP is allocated 1:1 to the intervention group 
or the control group, using unstratified randomisation 
with a random sequence of block sizes of two and four. An 
independent statistician, who is otherwise not involved 
in the trial, generated the randomisation list. To uphold 
the concealment of allocation only system administrators 
who are otherwise not involved in the trial can access the 
randomisation list.
Eligibility criteria
Inclusion criteria
GP level
To be eligible for participation, GPs must be participating 
in the ‘Family medicine ICPC Research using Electronic 
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Figure 2 OPTICA data flow chart. Step-by-step explanation of the data flow during the OPTICA trial. EMR, electronic medical 
record; FIRE, Family medicine ICPC Research using Electronic medical records; GPs, general practitioners; OPTICA, Optimising 
PharmacoTherapy In the multimorbid elderly in primary CAre; STRIPA, Systematic Tool to Reduce Inappropriate Prescribing-
Assistant.
medical records’ (FIRE) project led by the Institute of 
Primary Care of the University of Zurich.27 The EMR 
they use in their GP office have to be compatible with the 
FIRE database, which is a database with anonymous data 
from the EMR of more than 500 GPs in Switzerland. The 
database of the FIRE project contains administrative data, 
vital data, laboratory values, International Classification 
of Primary Care 2 (ICPC-2) codes for diagnoses and infor-
mation on medications prescribed. Participating GPs 
can, only for the purpose of this trial, identify individual 
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patients in the usually anonymous FIRE database, so that 
their data can be used in this trial. All participating GPs 
must complete an online training for Good Clinical Prac-
tice (GCP).
Patient level
Patients must be enlisted by one of the participating GPs, 
so that this GP is their main prescribing physician and 
they must see their GP regularly. The investigators left the 
definition of regularity to the judgement of participating 
physicians. Patients must be ≥65 years of age, have ≥three 
chronic diseases based on ICPC-2 coding or based on the 
GP’s clinical decision (multimorbidity), and regularly 
take ≥five medications (polypharmacy). Written informed 
consent must be sought from patients or, if patients suffer 
from cognitive impairment, their relative prior to enrol-
ment. This consent includes the right to obtain data from 
the FIRE project about the study participant.
Exclusion criteria
GP level
In group practices, only one GP can take part in the trial.
Patient level
To maximise the generalisability of the study population, 
the investigators kept exclusion criteria to a minimum. 
They excluded patients currently taking part in another 
interventional study.
Intervention
The intervention, a systematic medication review, 
includes the use of a web-based CDSS called ‘System-
atic Tool to Reduce Inappropriate Prescribing’-Assis-
tant (STRIPA), developed by a team from the Utrecht 
University and the University Medical Centre Utrecht 
in the Netherlands.28 STRIPA is based on all algorithms 
of the ‘Screening Tool of Older Person’s Prescriptions’ 
(STOPP) and ‘Screening Tool to Alert doctors to Right 
Treatment’ (START) criteria V.2,29 which are expert-con-
sensus lists of inappropriate and appropriate medications 
for older adults that consider coexisting medical condi-
tions and are thus suited for optimising the prescrip-
tions of multimorbid older patients.30 STRIPA combines 
implicit and explicit prescribing tools and takes a stepped 
approach that actively encourages patient involvement in 
decision-making.28 31 Taking into account medications, 
diagnoses, laboratory values and vital data, the STRIPA 
generates recommendations for physicians about ‘under-
prescribing, ineffective prescribing, overprescribing, side 
effects, contraindications, (…) drug–drug and drug–
disease interactions, incorrect dosages/dosing frequen-
cies and practical intake issues’.28 The intervention’s 
recommendations allow patients and GPs to conduct a 
shared decision-making process about patients’ medica-
tion intake, so patient preferences play an important role 
in this trial.
A STRIPA validation study with GPs based on two 
test cases showed appropriate prescribing decisions 
increased and inappropriate decisions decreased during 
a medication review of an older, multimorbid patient with 
polypharmacy.31 STRIPA is being tested in the European 
multicentre clinical trial ‘OPtimising thERapy to prevent 
Avoidable hospital admissions in Multimorbid older 
people’ (the OPERAM trial) in the hospital setting to find 
out if it can reduce drug-related hospital re-admissions.32
This study adapted the intervention from the OPERAM 
trial so it could be tested in the primary care setting.33 
The intervention comprises six steps:
1. This data will be imported from the FIRE database 
into the STRIPA: patients’ baseline characteristics 
(eg, sex, age); vital data and laboratory measurements 
(eg, kidney function, blood pressure), patients’ signs 
and symptoms, different scores (eg, HAS-BLED score 
for major bleeding risk), ICPC-2 coded diagnoses, 
and medications entered as Anatomical Therapeutic 
Chemical codes.
2. GPs log in to STRIPA and see a list with their recruit-
ed patients’ identifiers. When they click on a pa-
tient’s ID, the information exported from the EMR to 
STRIPA via FIRE becomes visible (from Step 1). The 
GP can add unrecorded values or adjust values (eg, 
when more recent laboratory values are available). 
This might be necessary because it might take some 
time to obtain the FIRE data and to import it to STRI-
PA and hence the information might change in the 
meantime.
3. GPs use a drag and drop function to link each medica-
tion to a diagnosis.
4. GPs run the analysis in STRIPA and then look at STRI-
PA’s recommendations. After the analysis is finished, 
STRIPA records the recommendations it generates so 
that they will be available for later analysis and gener-
ates a PDF report that can be saved by GPs.
5. GPs then must decide if they agree with STRIPA’s ad-
vice given and if they will present it to their patient. 
They can follow, partly follow, or decline STRIPA’s rec-
ommendations.
6. At the next appointment with the same patient, GPs 
will present the recommendations that they consider 
appropriate. GP and patient will decide together, in a 
shared decision-making process, which recommenda-
tions to implement. GPs will work from a checklist that 
explains how to conduct the shared decision-making 
process so that the patients’ preferences are met. The 
shared-decision making process is based on Elwyn et 
al’s model34 and was adapted from the OPERAM trial. 
The four key elements of this shared decision-making 
process are ‘choice talk’, ‘option talk’, ‘preference 
talk’, and ‘decision talk’.34 Patients may follow, partly 
follow or decline the recommendations. Because mul-
timorbid patients are likely to have multiple prescrib-
ers, GPs and patients can discuss recommendations 
with other prescribers, for example, specialists. The 
GP records in the REDCap study database the patient’s 
decisions and the reasons recommendations were ac-
cepted, partially accepted, or declined. These records 
will be analysed later.
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Before the intervention, GPs in the intervention group 
will watch an instruction video and read training material 
that will guide them through the intervention step-by-step.
sham intervention
Patients assigned to the control arm receive a sham inter-
vention from their GP—a medication discussion in accor-
dance with usual care. This means that the GP will, as 
usual in standard care, ask the patient if the current list of 
medication is complete or needs to be adapted, then share 
decision making with the patient about possible changes. 
The GPs who do the sham intervention will receive the 
same shared decision-making checklist as the GPs in the 
intervention group. The investigators explicitly ask GPs 
not to deviate from their usual practice when they review 
the patients’ medication and not to use additional tools. 
After the sham intervention, GPs record procedures, 
decisions, and reasons in the REDCap study database for 
later analysis. This sham intervention ensures that the 
medication list of control group study participants, which 
will be used to assess study outcomes, is up-to-date, while 
also ensuring patients are blinded.
screening and enrolment
For patient recruitment, the investigators use data from 
the FIRE project to prepare a screening list for each GP 
that contains a random selection of eligible patients. 
On each screening list, there are about 20 patients who 
were randomly sampled from all enlisted patients after 
they met the age criteria and were determined to regu-
larly take at least five chronic medications, based on the 
Pharmacy-based Cost Group model.35–37 Since ICPC-2 
coding is suboptimal in many GP offices, the investiga-
tors decided not to include the chronic disease criterion 
when they prepared the screening lists. From the list, GPs 
systematically recruit eight to 10 patients who meet the 
full inclusion criteria, which now include the number of 
chronic diseases, and do not meet any of the exclusion 
criteria. GPs will recruit patients starting either at the 
bottom of the list or the top. If GPs have finished the first 
screening list without recruiting the minimum amount 
of participants, the investigators will provide them with 
a second list.
Since the screening lists are compiled from a random 
patient sample from each GP office based on FIRE data, 
patients on the list may have been treated by a different 
GP who works in the same group practice. It is also 
possible that patients on the list changed their GP or 
have died. Since prescriptions frequently change,38 some 
patients with polypharmacy might not have qualified for 
the screening list when data was last exported. For all 
these reasons, the protocol allows GPs to skip patients 
on the screening list if they provide an explanation, or to 
recruit patients who are not on the list but fulfil the inclu-
sion and do not meet the exclusion criteria. After identi-
fying patients on the list and verifying their eligibility, GPs 
then inform the patient about the study and seek their 
informed consent. Study-related appointments are added 
to the patients’ regular appointments at no charge.
data collection
Study participants or their relatives are followed up by 
phone at baseline and at 6 and 12 months after study 
enrolment to collect data. At these times, complementary 
information from the FIRE database, including informa-
tion about medications and chronic diseases, is imported 
into the REDCap study database.27
blinding procedures
The OPTICA trial is blinded to the extent the cluster 
design of this RCT allows. The method of partial blinding, 
which is similar to that used in the OPERAM trial,32 is set 
out in detail in table 1.
Follow-up
Outcome information is collected at baseline, at 6, and 
at 12 months via telephone calls with patients or rela-
tives conducted by a blinded study team member, and 
through FIRE database exports. The study team will make 
every reasonable effort to keep each patient in the study 
until all planned treatments and assessments have been 
performed. But patients may withdraw from the study or 
be withdrawn when they are lost to follow-up.
Assessment of primary outcome
The primary endpoint is medication appropriateness, 
measured jointly by the MAI and the AOU, in each study 
group. While the AOU assesses underprescribing, the 
MAI is a tool to assess different elements of medication 
prescribing (eg, overprescribing, drug–drug interactions, 
etc).7 39 40
Blinded study team members assess the MAI for each 
regular medication study participants take and assess 
the AOU for each chronic condition study participants 
have. The investigators will use the weighted 10-item 
version of the MAI developed by Samsa et al.40 However, 
due to the rapidly changing drug prices the MAI item 
on cost-effectiveness will not be included. The criteria of 
the MAI, including corresponding weights, can be found 
in table 2. Using clinical data and the predefined opera-
tional definitions for each item, the assessor rates each 
medication on a three-point scale ranging from A=appro-
priate, B=marginally appropriate, C=inappropriate. Each 
‘inappropriate’ rating will receive the respective weight 
from table 2, while the weight of ratings ‘appropriate’ 
and ‘marginally appropriate’ will be 0. Thus, the score for 
each medication ranges from 0 to 17 (as the cost-effective-
ness criterion will not be included).40 A higher score indi-
cates a greater degree of medication inappropriateness. 
The investigators will calculate the score for each medi-
cation and then calculate the summated score for each 
patient, by summing up the scores for each medication. 
For the AOU, assessors decide for each chronic condition 
if there is (i) no omission, (ii) marginal omission, or (iii) 
omission of indicated medication.41–43 For each patient, 
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Table 1 Blinding status and measures to assure blinding
Role Blinding status How to achieve blinding
General practitioners Unblinded When screening for patients and seeking informed consent, GPs are still 
blinded, as each cluster (GP) will be only randomised after the cluster is full 
(8–10 patients). The screening list GPs use for recruitment contains a random 
sample of potentially eligible patients, which was generated from FIRE 
data by a blinded study team member. All this is done to prevent selection 
bias. However, since GPs can recruit patients outside this list, not all study 
participants are recruited randomly.
However, the study design makes it impossible to blind GPs throughout the 
trial. When GPs do the medication review/discussion, they know what group 
they are allocated to. Nevertheless, GPs in the control arm do not know the 
procedures in the intervention arm, which prevents cross-contamination; if they 
knew the procedure in the intervention arm, they might adapt their usual care.
Data collectors and 
assessors
Blinded The randomisation of GPs is kept concealed from the team that makes follow-
up calls to avoid interviewer bias. Data collectors and assessors have no 
access to unblinded study information in the database or to local source data. 
If a SAE occurs, the study coordinator and project manager will be informed.
Data manager and data 
analyst
Unblinded The investigators cannot blind the data managers and analysts because they 
can see the differences in data structure between the study groups. This is why 
the investigators will use a new data analyst to prepare a clean data set with 
truncated data to conduct a blinded analysis of the primary outcome.
Study coordinator and 
project manager, including 
principal investigator
Unblinded The study coordinator, project manager and the principal investigator of 
the trial know the treatment allocation. They are responsible for collecting 
information about SAEs and performing safety assessments.
Patients Partially blinded Patients stay partially blinded. They are only given a ‘high-level description’ 
of the study question so they know that their GP has been allocated to one of 
two study groups, but they do not know which one. To uphold patient blinding, 
patients in the control group will meet their GP for a medication discussion 
and a shared decision-making about their prescriptions. This means patients in 
each study arm see GPs the same number of times during the trial and cannot 
guess their allocation status based on the number of consultations.
The OPTICA trial’s approach to blinding resembles the approach used in the OPERAM trial.32
GP, General Practitioner; OPERAM, OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older peopl; OPTICA, 
Optimising PharmacoTherapy In the multimorbid elderly in primary CAre; SAE, serious adverse event.
the investigators will calculate how many omissions there 
are.
The MAI and the AOU will be assessed and calculated 
for baseline, the follow-up one at 6 months and the 
follow-up two at 12 months. For at least 32 cases (10% of 
the targeted sample size), two blinded investigators will 
conduct a blinded independent double assessment of 
the MAI and the AOU to check inter-rater reliability. The 
investigators will use information about diagnoses (coded 
in ICPC-2) and medication intake from the FIRE data-
base for these assessments.
Assessment of secondary outcomes
The following secondary outcomes are assessed at base-
line, 6 and 12 months (data source in brackets)
 ► Degree of polypharmacy; that is, the number of 
regular long-term medications patients take (FIRE 
database).
 ► Degree of overprescribing, measured by the MAI 
(assessment of FIRE data done by study team).
 ► Degree of underprescribing, measured by the AOU 
(assessment of FIRE data done by study team).
 ► Number of falls and fractures in the last six months 
(patient/relative phone call).
 ► Quality of life, based on the five-level version of the 
European Quality of Life-5 Dimensions question-
naire, including pain/discomfort44 45 (patient/rela-
tive phone call).
 ► Amount of formal care received in the last six months: 
number and length of stay of planned and unplanned 
hospitalisations; visits to the emergency room without 
inpatient hospitalisation; GP visits; medical specialist 
visits (differentiated by specialty); hospital outpatient 
visits; inpatient stays; length of stay at rehabilitation 
facilities; physiotherapist and other allied therapist 
visits; nursing home admissions (in patients who were 
living in the community at baseline); length of stay in 
nursing homes; and, number of home nursing visits 
(patient/relative phone call, except for number of GP 
visits which comes from FIRE database).
 ► Amount of informal care received in the last six 
months: unpaid care by, for example, family members, 
relatives, friends (patient/relative phone call).
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Table 2 Criteria of the Medication Appropriateness Index 
including weights
Item Weight
1 Is there an indication for the drug? 3
2 Is the medication effective for the 
condition?
3
3 Is the dosage correct? 2
4 Are the directions correct? 2
5 Are the directions practical? 1
6 Are there clinically significant drug–drug 
interactions?
2
7 Are there clinically significant drug–
disease/condition interactions?
2
8 Is there unnecessary duplication with 
other drug(s)?
1
9 Is the duration of therapy acceptable? 1
Item 10 ‘Is this drug the least expensive alternative 
compared to others of equal utility?’ has been 
excluded.40
 ► Survival (patient/relative phone call or reported by 
GP).
 ► QALYs accrued in one year,46 measured as a function 
of the length and the quality of life (calculated based 
on data from patient/relative phone call).
 ► Direct medical costs accrued in one year, measured by 
combining formal and informal healthcare resource 
use observed in the trial (patient/relative phone 
call), including the time GPs spend on the interven-
tion (reported by GP) and software costs (literature 
search), and Swiss unit costs from sources external to 
the trial (literature search).
 ► Cost-effectiveness of the intervention, calculated by 
combining clinical data (FIRE database), quality of 
life data (patient/relative phone call) and healthcare 
use data collected in the trial (patient/relative phone 
call).
The following outcome will be assessed after the 
intervention
 ► Percentage of STRIPA recommendations accepted 
and rejected by GPs (reported by GPs, cross-verified 
with STRIPA reports).
The following secondary outcome is assessed at base-
line only:
 ► Patients’ willingness to have medications depre-
scribed, measured with the validated ‘revised Patient 
Attitudes Towards Deprescribing’questionnaire47 48 
(patient/relative phone call).
Safety outcomes include adverse events, serious adverse 
events and device deficiencies.
study duration
GPs can recruit the patients over a period of at least 
six months, so they can integrate recruitment into their 
daily practice. Recruited patients are followed up for 
one year.
sample size
Sample size calculation is based on testing the two co-pri-
mary outcomes for superiority and uses the Bonfer-
roni-approach to account for multiple testing. Based 
on trial results published by Gallagher et al in 2011, the 
investigators assumed that 35% of patients in the control 
group and 60% of patients in the intervention group will 
improve their total MAI score (at least one less point) 
and that 10% of patients in the control group and 30% of 
patients in the intervention group will have a better AOU 
score (at least one fewer prescribing omission).49 Intra-
cluster correlations (ICC) of 0.01–0.05 are typically found 
for binary outcomes in elderly individuals.50 The investi-
gators conservatively assumed an ICC of 0.05 to calculate 
the sample size. The investigators fixed the type I error 
at a Bonferroni-corrected two-sided alpha level of 0.025.
Based on a two-sample comparison of proportions and a 
prespecified number of clusters of about 40 (about 20 per 
arm), seven patients per cluster are required to detect a 
difference of 25% between the two groups in the propor-
tion of improvement in the MAI, with a power of 90%. 
The number of 40 GPs was selected arbitrarily for feasi-
bility reasons. Using the same assumption for the AOU, 
the investigators found they also need seven patients per 
cluster to detect a difference of 20%. The investigators 
thus need a sample of 280 patients (140 per arm) to 
provide 81% power to detect a significant improvement 
in both the MAI score and the AOU. To account for attri-
tion from dropout or death (15% estimated), the number 
of patients per cluster was increased to eight (max. ten), 
so the final sample size should be about 320 patients (160 
per arm). The investigators will closely support GPs to 
help them reach the target sample size.
statistical analysis
In case data on outcomes are incomplete, the investi-
gators will use multiple imputation to replace missing 
values, taking data clustering into account. No interim 
analyses are planned.
There are two co-primary outcomes: improvement in 
the MAI at 12 months, defined as decrease of at least 
one point, and improvement in the AOU at 12 months, 
defined as at least one less prescribing omission. Both 
outcomes will be tested separately; success is indicated by 
the significance of at least one of the two tests.
For the co-primary outcomes, the investigators will 
present and compare the proportion of patients whose 
MAI and AOU score improved in the control and inter-
vention group. The relative difference between groups 
will be determined in a mixed-effects logistic model with 
a random intercept at the GP level to account for clus-
tering. The effect measure for the primary outcomes 
will be odds ratios (OR). The relative difference will be 
presented as OR with a 95% CI. The primary analysis 
will be an intention-to-treat analysis. In a per-protocol 
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analysis, the investigators will only evaluate patients who 
adhered to the protocol and exclude patients who violate 
any inclusion or exclusion criteria.
Secondary binary outcomes will be evaluated like the 
primary outcomes. Secondary continuous outcomes will 
be analysed using random-effects linear regression with 
a random intercept at the GP level. Models will also be 
adjusted for the baseline value as a covariate. Secondary 
count outcomes will be analysed using random-effects 
Poisson regression with a random intercept at the GP 
level.
Health economic analyses will assess (i) resource use 
and cost differences between the trial arms, (ii) differ-
ences in quality-adjusted lifetime between the trial arms, 
expressed as QALYs, and (iii) a comparison of cost-effec-
tiveness between intervention and standard care.
Because cluster-randomisation may not balance char-
acteristics between groups to match individual-level 
randomisation, the investigators will adjust each model 
for patient-level and physician-level variables to account 
for case-mix differences between groups and potential 
recruitment bias in a sensitivity analysis. They will also 
account for the correlated nature of data among GPs 
by using multilevel mixed-effects models. Unadjusted 
models will be provided for information only.
Patient and public involvement
Multimorbid, older patients with polypharmacy are 
represented in the independent Safety and Data Moni-
toring Board of the OPTICA trial. Throughout the trial, 
the Safety and Data Monitoring Board, which will consist 
of one GP, one statistician and one multimorbid, older 
layperson with polypharmacy, will meet regularly to 
discuss safety and data management issues. Patients are 
not actively involved in recruiting study participants, but 
play a key role in shared decision-making during the 
intervention and sham intervention. The investigators 
have created a priority list of questionnaire components 
to reduce the burden of the intervention on very old and 
sick study participants by reducing the duration of the 
follow-up calls where necessary. At the end of the study, 
the investigators will disseminate the results to study 
participants in a letter.
dIsCussIon
This protocol paper highlights the features of the OPTICA 
trial, the first RCT in primary care to test an intervention 
based on the STRIPA clinical decision support tool, which 
helps GPs customise medication reviews and optimise 
polypharmacy in older multimorbid patients.
This clinical trial compares the effect of a structured 
medication review on medication appropriateness in 
a Swiss primary care setting to a sham intervention. 
Systematic medication review may facilitate shared deci-
sion-making and improve medication appropriateness, 
especially for GPs who treat complex multimorbid 
patients with polypharmacy. It may also improve patients’ 
quality of life and health economic outcomes. This 
trial will add to the literature, as it examines in a real 
life setting a software-based intervention, which imple-
ments the STOPP/START criteria, based on data from 
electronic medical records. If successful, this study will 
demonstrate the usefulness of an electronic database, 
with coded data collected routinely in primary care, to 
be used in a clinical decision support tool. Additionally, it 
focuses on multimorbid patients who are often excluded 
from trials.
OPTICA is subject to the following limitations
 ► Despite taking precautions to avoid and reduce selec-
tion bias (cluster randomisation to avoid learning 
effect, screening lists for patient recruitment, rando-
misation of GPs after patient recruitment), selection 
bias is still possible because of the study design. Since 
GPs can recruit patients outside of the screening list 
for practical reasons, not all patients are recruited 
randomly. Patients who are more engaged and/or 
more likely to adhere to advice may be more likely 
to be enrolled in the trial, which might decrease the 
representativeness of the study population and the 
generalisability of the results. The investigators will 
use data from FIRE to compare the characteristics of 
study participants with those of non-participants.
 ► The investigators chose a usual care sham interven-
tion in the control group to improve patient blinding, 
but this design does not eliminate the risk GPs in the 
control group will be contaminated by the thematic 
of the trial (risk of deviating from their previous 
routine prescribing practices). In addition, this sham 
intervention might lead GPs to suggest medication 
changes that could improve the appropriateness of 
patients’ medications.
 ► Outcome assessment is based on self-reported data 
from patients and relatives and on data from FIRE, 
so some events may be missed. To ensure FIRE data is 
as complete as possible, GPs must code their patient’s 
medication intake and their diagnoses correctly. Diag-
noses require ICPC-2 codes. GPs were instructed, in 
face-to-face meetings, about how to code and update 
data in their EMR for patients in this trial.26
 ► Like all interventions that take an eHealth approach 
(STRIPA intervention in this case), people have 
different perceptions of what is user-friendly. New 
procedures may seem complicated in comparison 
to usual care. The investigators tried to simplify the 
process by (i) using EMR data so that GPs do not 
have to enter all the data themselves, but only update 
them if needed; and (ii) giving detailed instructions 
for using STRIPA in writing and in an online video 
training.
 ► Unrestricted randomisation designs, such as the block 
randomisation used in this trial, are more likely to 
result in imbalance of factors by chance.51
 ► Another limitation of the study is the restriction 
to self-control during the intervention, as it is a 
mono-professional intervention, and that the scope 
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of the intervention is limited to the use of the soft-
ware-based CDSS. However, due to the structure of the 
Swiss primary healthcare setting this design is feasible 
in a real life setting, whereas multiprofessional inter-
ventions would be difficult to organise.
 ► The primary outcome of this trial is not directly 
patient-relevant. However, directly patient-relevant 
outcomes, such as quality of life, figure among the 
secondary outcomes of this trial.
It may be difficult to follow-up multimorbid, older 
patients, who are often excluded from trials.52 The investi-
gators believe that the task is worth the effort because trial 
results need to be generalisable to exactly this population. 
To reduce the duration of the phone calls with particu-
larly weak study participants only the core elements of the 
study questionnaire will be used, if necessary, based on a 
predefined priority list.
The OPTICA trial has the following strengths:
 ► The OPTICA trial is the first RCT to examine the 
effect of STRIPA on medication appropriateness in 
older, multimorbid patients with polypharmacy in a 
primary care setting.
 ► OPTICA is the first RCT to test the use of soft-
ware-based structured medication reviews in Swiss 
primary care.
 ► OPTICA demonstrates the usefulness of coding and 
linking data from EMR, and re-using this data to 
evaluate primary care interventions in a randomised 
controlled trial setting.
 ► In the OPTICA trial, the investigators do not exclude 
patients with cognitive impairment if a relative gives 
their informed consent, because patients with cogni-
tive impairment are especially prone to polypharmacy, 
yet they have been excluded from many other trials.
ConClusIon
The OPTICA trial will compare the effect of the system-
atic medication review that uses STRIPA, including shared 
decision-making, to usual care (sham intervention) with 
the goal of improving medication appropriateness. The 
investigators expect the intervention to improve the 
quality of life and health status of a rapidly ageing popu-
lation with increasing multimorbidity and polypharmacy. 
The study results will inform other studies and interven-
tions designed to optimise medication use by integrating 
a CDSS with electronic medical records.
Current status of the oPtICA trial
The patient recruitment in the OPTICA trial began in 
December 2018. By early July 2019, 278 patients (about 
85% of the target sample size) have been recruited. The 
investigators have randomised 31 out of about 40 GPs. 
Last patient out is expected in the second half of 2020.
Ethics
All participant data will be handled according to the prin-
ciples of the Declaration of Helsinki.53 The OPTICA trial 
complies with all applicable standards of the guideline for 
Good Clinical Practice of the International Conference 
on Harmonisation (ICH-GCP).54
Data management, monitoring, safety reporting and 
audits meet the requirements of the Swiss law. The inves-
tigators uphold the principle of patients’ right to privacy 
and comply with applicable privacy laws. Confidentiality 
and anonymity of the patients shall be guaranteed when 
the data is presented at scientific meetings or published 
in scientific journals. Only selected study team members 
will have access to the final trial dataset.
Risks, including human failure and software malfunc-
tion, cannot be excluded. But STRIPA only makes 
prescription recommendations to GPs in the interven-
tion group. Participating GPs are experienced (mean 
age of experience as GP: 16 years), and will take the 
final decision about whether to accept the recommen-
dations and to present them to the patient. Patients 
thus are not exposed to more risk than they would be in 
standard care. This clinical trial entails minimal risk for 
participants and the benefit-risk ratio is positive. Basler 
Versicherungen will provide insurance and cover eventual 
damages.
Participating GPs have signed a non-disclosure 
agreement.
dissemination
OPTICA embraces an open access policy and will vigor-
ously disseminate all resulting data, study results and 
publications. The investigators closely collaborate with 
the National Research Programme 74 (NRP74) 'Smarter 
Health Care' to optimise dissemination of the study 
results to the public.
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